Seventure Partners is a French venture capital manager that finances innovative companies "depuis l'amorcage jusqu'au capital-developpement" (from seed through development capital). Its stated expertise is organised in two departments, Sciences de la vie (life sciences) and Technologies digitales (digital technologies), with a third Sport & bien-etre theme. Life sciences sub-sectors it names are microbiome, nutrition, foodtech and wellbeing, medical devices, digital and connected health, pharmaceuticals, industrial biotechnology, the blue economy and animal health and nutrition. Digital sub-sectors it names are fintech, retailtech, hardware and telecom and other innovative digital solutions. The firm says it looks for companies addressing a significant market and holding a technology or know-how that gives a durable competitive advantage, that it stays in the capital for periods that can exceed 10 years, and that it generally takes a seat on the board or supervisory board of the companies it finances. Its shareholder engagement policy states that Seventure generally asks for a seat on governance bodies of unlisted holdings depending on the weight of the investment, the stage and the geography. It runs several distinct fund ranges rather than a single flagship series: Health For Life Capital and Health for Life Capital II (microbiome, health and nutrition), Digital Opportunities Fund (fintech, insurtech, regtech, retailtech in France and Germany), Sport & Performance Capital (sport and wellbeing), Quadrivium 1 Seed Fund (seed, from twelve academic partners), the AVF fund (animal health, feed and nutrition, cornerstoned by Adisseo), Blue Forward Fund (blue economy) and retail FCPI vehicles. It is headquartered in Paris; its Venture Partners are described on the team pages as based in Geneva, London, Munich, Basel, Berlin and Paris.
€779M (under management as at 30 June 2026, per the Natixis Investment Managers affiliate page; Seventure's own About page states 1 Md EUR under management as at 30 June 2024) AUM71/100 Power Score™1997 FoundedParis, France
Life SciencesBiotechFoodtechMedical DevicesDigital HealthPharmaceuticalsSynthetic BiologySustainabilityTechnologyFintechRetailHardwareConsumer
Seventure Partners is created ("Creee en 1997", per the firm's own Notre histoire page).
2001
Isabelle de Cremoux joins Seventure to establish the Life Sciences division.
2012
Seventure Partners acquires Masseran Gestion in July 2012; David Manjarres and Thibault Canton join the firm as part of that acquisition.
2013
The Fonds d'amorcage Quadrivium 1 seed fund is created in November 2013 (EUR 56m), investing alongside twelve academic partners.
2014
Santaris, a Seventure portfolio company, is sold to Roche for USD 450 million in August 2014.
2019
Health for Life Capital II announces its first close on 5 March 2019.
2019
Sport & Performance Capital announces its first close on 11 July 2019.
2021
MaaT Pharma, a Seventure portfolio company, lists on the Euronext Paris regulated market on 8 November 2021 (ticker MAAT).
2022
Seventure Partners announces the first close of Blue Forward Fund on 11 February 2022, a blue-economy fund with a EUR 130 million target backed by the Banque Populaire banks.
2026
Seventure Partners takes a stake in the French sailboat refurbishment company Reboat through the Blue Forward Fund (announced 23 July 2026).